American Heart Journal
Volume 145, Issue 6 , Pages 971-978 , June 2003

What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?

  • Steven Steinhubl, MD

      Affiliations

    • University of North Carolina, Chapel Hill, NC, USA
    • Corresponding Author InformationReprint requests: Steven Steinhubl, MD, Division of Cardiology, University of North Carolina, CB#7075, 338 Burnett-Womack Building, Chapel Hill, NC 27599-7075, USA.
    • ,
  • Peter Berger, MD

      Affiliations

    • Mayo Clinic, Rochester, Minn, USA

Received 13 May 2002 ,Accepted 14 October 2002.

References 

  1. Topol EJ. Coronary-artery stents–gauging, gorging, and gouging. N Engl J Med. 1998;339:1702–1704
  2. Lane DM. Dramatic increase in use of coronary stents. [letter] Am J Cardiol. 1999;84:1141
  3. Schühlen H, Kastrati A, Pache J, et al.  Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement (analysis of 5678 patients with a four-week ticlopidine regimen). J Am Coll Cardiol. 2001;37:2066–2073
  4. Wilson SH, Rihal CS, Bell MR, et al.  Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. Am J Cardiol. 1999;83:1006–1011
  5. Schwartz L, Bourassa MG, Lesperance J, et al.  Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988;318:1714–1719
  6. Barnathan ES, Schwartz JS, Taylor L, et al.  Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation. 1987;76:125–134
  7. Mak K-H, Belli G, Ellis SG, et al.  Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol. 1996;27:494–503
  8. Serruys PW, de Jaegere P, Kiemeneij F, et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489–495
  9. Fischman DL, Leon MB, Baim DS, et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501
  10. Steinhubl SR, Lauer MS, Mukherjee DP, et al.  The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol. 1998;32:1366–1370
  11. Steinhubl SR, Ellis SG, Wolski K, et al.  Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events (data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial). Circulation. 2001;103:1403–1409
  12. Chew DP, Bhatt DL, Robbins MA, et al.  Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 2001;88:672–674
  13. Assali AR, Salloum J, Sdringola S, et al.  Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Am J Cardiol. 2001;88:884–886
  14. Colombo A, Hall P, Nakamura S, et al.  Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676–1688
  15. Uretsky BF, Rosanio S, Lerakis S, et al.  A prospective evaluation of angiography-guided coronary stent implantation with high versus very high balloon inflation pressure. Am Heart J. 2000;140:804–812
  16. The EPISTENT Investigators . Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87–92
  17. The ESPRIT Investigators . Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) (a randomised, placebo-controlled trial). Lancet. 2000;356:2037–2044
  18. O’shea JC, Hafley GE, Greenberg S, et al.  Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial (a randomized controlled trial). JAMA. 2001;285:2468–2473
  19. O’Neill WW, Serruys P, Knudtson M, et al.  Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. N Engl J Med. 2000;342:1316–1324
  20. Cannon CP, McCabe CH, Wilcox RG, et al.  Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;102:149–156
  21. The SYMPHONY Investigators . Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes (a randomised trial). Lancet. 2000;355:337–345
  22. Second SYMPHONY Investigators . Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation. 2001;103:1727–1733
  23. Chew DP, Bhatt DL, Sapp S, et al.  Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists (a meta-analysis of phase III multicenter randomized trials). Circulation. 2001;103:201–206
  24. Topol EJ, Easton JD, Amarenco P, et al.  Design of the Blockade of the glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial. Am Heart J. 2000;139:927–933
  25. BRAVO trial stopped: lotrafiban increases mortality. www.cardiosource. Available at: http://www.cardiosource.com/trials/trial?searchtoc=B&published=n&uid=MDTRIALS.32868&hi=bravo+or+stopped. Accessed 2000
  26. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206–1218
  27. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998;129:394–405
  28. Steinhubl SR, Tan WA, Foody JM, et al.  Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA. 1999;281:806–810
  29. Fuster V, Stein B, Ambrose JA, et al.  Atherosclerotic plaque rupture and thrombosis (evolving concepts). Circulation. 1990;82:II47–II59
  30. Mills DC, Puri R, Hu CJ, et al.  Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb. 1992;12:430–436
  31. Bossavy J-P, Thalamas C, Sagnard L, et al.  A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood. 1998;92:1518–1525
  32. Cadroy Y, Bossavy J-P, Thalamas C, et al.  Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation. 2000;101:2823–2828
  33. Herbert J-M, Dol F, Bernat A, et al.  The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost. 1998;80:512–518
  34. Bertrand ME, Legrand V, Boland J, et al.  Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation. 1998;98:1597–1603
  35. Hall P, Nakamura S, Maiello L, et al.  A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996;93:215–222
  36. Leon MB, Baim DS, Popma JJ, et al.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339:1665–1671
  37. Schömig A, Neumann F-J, Kastrati A, et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084–1089
  38. Urban P, Macaya C, Rupprecht H-J, et al.  Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients. The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation. 1998;98:2126–2132
  39. Müller C, Büttner HJ, Petersen J, et al.  A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation. 2000;101:590–593
  40. Bertrand ME, Rupprecht H-J, Urban P, et al.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation. 2000;102:624–629
  41. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation. 2001;104:539–543
  42. Van De Graaff E, Steinhubl SR. Antiplatelet medications and their indications in preventing and treating coronary thrombosis. Ann Med. 2000;32:561–571
  43. Bachmann F, Savcic M, Hauert J, et al.  Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel. [abstract] Eur Heart J. 1996;17(Suppl):263
  44. Di Perri T, Pasini FL, Frigerio C, et al.  Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration. Eur J Clin Pharmacol. 1991;41:429–434
  45. Yusuf S, Zhao F, Mehta SR, et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
  46. Thel MC, Califf RM, Tardiff BE, et al.  Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Am J Cardiol. 2000;85:427–434
  47. Cannon CP, Weintraub WS, Demopoulos LA, et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887
  48. van Domburg RT, Foley DP, de Feyter PJ, et al.  Long-term clinical outcome after coronary balloon angioplasty (identification of a population at low risk of recurrent events during 17 years of follow-up). Eur Heart J. 2001;22:934–941
  49. Hannan EL, Racz MJ, Arani DT, et al.  A comparison of short- and long-term outcomes for balloon angioplasty and coronary stent placement. J Am Coll Cardiol. 2000;36:395–403
  50. de Feyter PJ, de Jaegere PPT, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J. 1994;127:643–651
  51. Rupprecht HJ, Darius H, Borkowski U, et al.  Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation. 1998;97:1046–1052
  52. Pietersma A, Kofflard M, de Wit LE, et al.  Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation. 1995;91:1320–1325
  53. Hoffmann R, Mintz GS, Dussaillant GR, et al.  Patterns and mechanisms of in-stent restenosis (a serial intravascular ultrasound study). Circulation. 1996;94:1247–1254
  54. Smith SC, Dove JT, Jacobs AK, et al.  ACC/AHA Guidelines for percutaneous coronary intervention (executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty)). J Am Coll Cardiol. 2001;37:2215–2238
  55. van Domburg RT, Foley DP, de Jaegere PP, et al.  Long term outcome after coronary stent implantation (a 10 year single centre experience of 1000 patients). Heart. 1999;82(2 Suppl):II27–II34
  56. Savage MP, Goldberg S, Bove AA, et al.  Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty (Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II) for the M-HEART II Study Group). Circulation. 1995;92:3194–3200
  57. ten Berg JM, Kelder JC, Suttorp MJ, et al.  Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up (a randomized trial). Circulation. 2000;102:386–391
  58. ten Berg JM, Hutten BA, Kelder JC, et al.  Oral anticoagulant therapy during and after coronary angioplasty: the intensity and duration of anticoagulation are essential to reduce thrombotic complications. Circulation. 2001;103:2042–2047
  59. Mehta SR, Yusuf S, Peters RJG, et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention (the PCI-CURE study). Lancet. 2001;358:527–533
  60. Mehta SR, Yusuf S  CURE Study Investigators . The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme (rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease). Eur Heart J. 2000;21:2033–2041
  61. Teirstein PS, Kuntz RE. New frontiers in interventional cardiology (intravascular radiation to prevent restenosis). Circulation. 2001;104:2620–2626
  62. Teirstein P, Reilly JP. Late stent thrombosis in brachytherapy (the role of long-term antiplatelet therapy). J Invasive Cardiol. 2002;14:109–114
  63. Kuntz RE, Tierstein PS, Ho KKL, et al.  The major risk factor for late thrombosis following gamma radiation for in-stent restenosis is new stent use. J Am Coll Cardiol. 2001;37(A Suppl):8A
  64. Waksman R, Ajani AE, White RL, et al.  Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary γ-radiation in patients with in-stent restenosis (Washington Radiation for In-Stent Restenosis Trial Plus 6 months of Clopidogrel (WRIST PLUS)). Circulation. 2001;103:2332–2335
  65. Teirstein PS, Moses JW, Casterella PJ, et al.  Late thrombosis after coronary radiation may be eliminated by longer antiplatelet therapy and reduced stenting (the Scripps III results). J Am Coll Cardiol. 2001;37(A Suppl):60A
  66. Morice MC, Serruys PW, Sousa JE, et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
  67. Almony GT, Lefkovits J, Topol EJ. Antiplatelet and anticoagulant use after myocardial infarction. Clin Cardiol. 1996;19:357–365

☆ Supported by an unrestricted educational grant from Sanofi-Synthelabo and Bristol-Myers Squibb Company.

PII: S0002-8703(03)00104-2

doi: 10.1016/S0002-8703(03)00104-2

American Heart Journal
Volume 145, Issue 6 , Pages 971-978 , June 2003

Article Tools

* Image Usage & Resolution